AD-209 / Yuhan Corp - LARVOL DELTA

Efficacy and safety of low-dose antihypertensive combination drugs including amlodipine, telmisartan, and chlorthalidone: a multicenter, randomized, double-blinded, parallel, phase III clinical trial (ESC-WCC 2025) - "In conclusion, this study suggests that AD-209, a low-dose combination of telmisartan (20 mg), amlodipine (2.5 mg), and chlorthalidone (6.25 mg) provides a significant blood pressure-lowering effect compared to telmisartan (40 mg), in patients with essential hypertension, with a similar safety profile."

Clinical • P3 data • Cardiovascular • Hypertension

Phase III Study to Evaluate the Efficacy and Safety of AD-209 (clinicaltrials.gov) - P3 | N=280 | Recruiting | Sponsor: Addpharma Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Hypertension

A Study to Evaluate the Efficacy and Safety of AD-209 (clinicaltrials.gov) - P2 | N=221 | Completed | Sponsor: Addpharma Inc. | Recruiting ➔ Completed | Trial completion date: Mar 2024 ➔ Nov 2023 | Trial primary completion date: Mar 2024 ➔ Nov 2023

Trial completion • Trial completion date • Trial primary completion date • Cardiovascular • Hypertension

Phase III Study to Evaluate the Efficacy and Safety of AD-209 (clinicaltrials.gov) - P3 | N=280 | Not yet recruiting | Sponsor: Addpharma Inc.

New P3 trial • Cardiovascular • Hypertension

A Study to Evaluate the Efficacy and Safety of AD-209 (clinicaltrials.gov) - P2 | N=200 | Recruiting | Sponsor: Addpharma Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Hypertension

A Study to Evaluate the Efficacy and Safety of AD-209 (clinicaltrials.gov) - P2 | N=200 | Not yet recruiting | Sponsor: Addpharma Inc.

New P2 trial • Cardiovascular • Hypertension

Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension (clinicaltrials.gov) - P2; N=176; Completed; Sponsor: Addpharma Inc.; Active, not recruiting ➔ Completed

Clinical • Trial completion • Hypertension

Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension (clinicaltrials.gov) - P2; N=175; Active, not recruiting; Sponsor: Addpharma Inc.; Not yet recruiting ➔ Active, not recruiting; Trial completion date: Jul 2020 ➔ Feb 2021; Trial primary completion date: Jul 2020 ➔ Feb 2021

Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Hypertension

Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension (clinicaltrials.gov) - P2; N=175; Not yet recruiting; Sponsor: Addpharma Inc.

Clinical • New P2 trial